CN101370509A - 化合物连同γ辐射在用于治疗癌症中的应用 - Google Patents

化合物连同γ辐射在用于治疗癌症中的应用 Download PDF

Info

Publication number
CN101370509A
CN101370509A CNA200780002382XA CN200780002382A CN101370509A CN 101370509 A CN101370509 A CN 101370509A CN A200780002382X A CNA200780002382X A CN A200780002382XA CN 200780002382 A CN200780002382 A CN 200780002382A CN 101370509 A CN101370509 A CN 101370509A
Authority
CN
China
Prior art keywords
compound
alkyl
phenyl
unbranched
unsaturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200780002382XA
Other languages
English (en)
Chinese (zh)
Inventor
里卡德·格拉斯
徐红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ONCOREG AB
Original Assignee
ONCOREG AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ONCOREG AB filed Critical ONCOREG AB
Publication of CN101370509A publication Critical patent/CN101370509A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNA200780002382XA 2006-01-13 2007-01-15 化合物连同γ辐射在用于治疗癌症中的应用 Pending CN101370509A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75908806P 2006-01-13 2006-01-13
US60/759,088 2006-01-13

Publications (1)

Publication Number Publication Date
CN101370509A true CN101370509A (zh) 2009-02-18

Family

ID=36609604

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200780002382XA Pending CN101370509A (zh) 2006-01-13 2007-01-15 化合物连同γ辐射在用于治疗癌症中的应用

Country Status (8)

Country Link
US (2) US20100168038A1 (enExample)
EP (2) EP2160196A2 (enExample)
JP (2) JP2009523157A (enExample)
KR (1) KR20080085035A (enExample)
CN (1) CN101370509A (enExample)
AU (1) AU2007204314A1 (enExample)
CA (1) CA2636533A1 (enExample)
WO (2) WO2007088099A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111603560A (zh) * 2020-06-22 2020-09-01 泉州台商投资区秋鑫茶业有限公司 茶叶γ-氨基丁酸在肿瘤放射治疗上的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009000297A1 (en) * 2007-06-25 2008-12-31 Oncoreg Ab Tpp ii inhibitors for use in combination with chemotherapy for the treatment of cancer
US20100240591A1 (en) * 2007-06-25 2010-09-23 Oncoreg Ab Tpp ii inhibitors for use in the treatment of autoimmune and inflammatory diseases and transplant rejection
WO2009052116A1 (en) * 2007-10-15 2009-04-23 The Salk Institute For Biological Studies Methods for treating a variety of diseases and conditions, and compounds useful therefor
US8362068B2 (en) 2009-12-18 2013-01-29 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
CN103189067A (zh) * 2010-06-16 2013-07-03 密执安大学评议会 Wdr5与其结合配偶体的相互作用的抑制及治疗方法
AU2011348220B2 (en) * 2010-12-22 2017-09-07 The Salk Institute For Biological Studies Cyclic CRF antagonist peptides
AU2014323008B2 (en) 2013-09-23 2018-02-08 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Anti-inflammatory tripeptides
JP2017525684A (ja) * 2014-07-24 2017-09-07 ノーレックス インコーポレイテッド Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9106772A (pt) * 1990-08-22 1993-07-20 Syntello Vaccin Dev Kb Companh Processo para tratar e evitar a infeccao por virus da imunodeficiencia humana em individuos mamiferos,incluindo o homem,dispositivo atomizador,composicoes para aplicacoes topica,administracao gastrointestinal,parenteral,transdermica,para revestir equipamento medico,revestimento polimerico e peptideos
US5627035A (en) * 1990-08-22 1997-05-06 Syntello Vaccine Development Ab Peptides that block human immunodeficiency virus and methods of use thereof
WO1999033801A1 (en) * 1997-12-23 1999-07-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tripeptidyl peptidase inhibitors
US6258932B1 (en) * 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
DE10105039A1 (de) * 2001-02-05 2002-08-08 Tell Pharm Ag Hergiswil Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
EP1436317A1 (en) * 2001-09-19 2004-07-14 Tripep Ab Molecules that block viral infectivity and methods of use thereof
US20040097422A1 (en) * 2002-06-14 2004-05-20 Karl Munger Methods of use for tripeptidyl peptidase II inhibitors as anticancer agents
EP1716247A1 (en) * 2004-01-31 2006-11-02 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with tripeptidyl-peptidase 2 (tpp2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111603560A (zh) * 2020-06-22 2020-09-01 泉州台商投资区秋鑫茶业有限公司 茶叶γ-氨基丁酸在肿瘤放射治疗上的应用

Also Published As

Publication number Publication date
EP1971357A2 (en) 2008-09-24
KR20080085035A (ko) 2008-09-22
WO2007088099A3 (en) 2007-11-08
US20090227521A1 (en) 2009-09-10
EP2160196A2 (en) 2010-03-10
US20100168038A1 (en) 2010-07-01
WO2007088099A2 (en) 2007-08-09
CA2636533A1 (en) 2007-07-19
WO2007080194A3 (en) 2008-02-14
AU2007204314A1 (en) 2007-07-19
WO2007080194A2 (en) 2007-07-19
JP2009523157A (ja) 2009-06-18
JP2009523156A (ja) 2009-06-18

Similar Documents

Publication Publication Date Title
CN101370509A (zh) 化合物连同γ辐射在用于治疗癌症中的应用
RU2539832C2 (ru) Пептиды цитоплазматического домена белка muc-1 в качестве ингибиторов раковых заболеваний
US12485174B2 (en) HDAC6-activated macrophages, compositions, and uses thereof
KR102674191B1 (ko) 뇌암 줄기 세포의 성장, 이동 및 침습성 감소 그리고 뇌종양을 가진 환자의 생존 개선 방법 및 조성물
BR112012000098B1 (pt) Processo para a identificação de compostos para tratar câncer
CN1816564B (zh) 能选择性杀伤癌细胞的RasGAP衍生肽
MX2010014173A (es) Peptidos de señalizacion de la crkl.
US20140199309A1 (en) Fragment of secreted heat shock protein-90alpha (hsp90alpha) as vaccines or epitope for monoclonal antibody drugs or target for small molecule drugs against a range of solid human tumors
US20030202938A1 (en) Hematopoietic growth factor inducible neurokinin-1 gene
JP2013535954A (ja) ペプチド、構造体およびその使用
Orbán et al. A new daunomycin–peptide conjugate: synthesis, characterization and the effect on the protein expression profile of HL-60 cells in vitro
EP3804759A1 (en) Method for treating and/or preventing regnase-1-related disease
US20100240591A1 (en) Tpp ii inhibitors for use in the treatment of autoimmune and inflammatory diseases and transplant rejection
WO2009000297A1 (en) Tpp ii inhibitors for use in combination with chemotherapy for the treatment of cancer
AU2008220967B2 (en) Use of inhibitors of the degradation of p27, in particular Argyrin and derivatives thereof, for the treatment of proliferative diseases
US20220348620A1 (en) Engineered Peptide and Peptide Mimetic Compositions and Methods
Hong et al. Tripeptidyl-peptidase II controls DNA damage responses and in vivo γ-irradiation resistance of tumors
Huang Development of Improved Survivin Dimerization Inhibitors for Castration-Resistant Prostate Cancer
US20220096594A1 (en) Macrocyclic peptides for targeted inhibition of autophagy
JP2023103155A (ja) がん治療用医薬組成物およびがん治療薬をスクリーニングする方法
ES2253028B1 (es) "empleo del gen slug, sus productos de transcripcion o expresion, y/o compuestos inhibidores o estimuladores de la expresion de slug para conferir radioresistencia o radioproteccion celular.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090218